Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by zxcvbnnmon Mar 15, 2018 9:18am
76 Views
Post# 27718950

RE:RE:I'm Concerned About The Intentions Of Management?

RE:RE:I'm Concerned About The Intentions Of Management?Or the other way around, sell or wind down the loan division and then distribute a special dividend to shareholders. This is much easier as the LOI for the billing division is not a outright cash deal. It is $1.5M and plus an earn-out up to $10M which could take years to accomplish. That is perhaps why Brann dropped this one. 

According to your theory, since RBP was sold to a bunch of insiders in shares, including Brann. He would be fully incentived to distribute a special dividend again like he did last time at 7.5 cents once the loan division is sold or wind down. At this depressed price level as of now, such distribution will help the share price at least recover close to net book value.

Keep in mind, the liquidity of the stock is very low. It took only 1M volumn trading to bring the price down from 25 cents to 19 cents. Conversely, It will also only take 1M volumn for the price to recover from 17 cents to 23 cents. Be prepare to take off anytime once the news is out.  

Who are picking up those cheap shares? I am one of them. I bought some at 17 cents. I will continue to buy should it drop to 15 cents. With breakeven operating result, no debt, 37.4 cents net cash position, how lower this one could go? 
Bullboard Posts